6533b874fe1ef96bd12d6368
RESEARCH PRODUCT
Branch retinal vein occlusion associated with the 20210 G-to-A prothrombin variant.
A. VayaManuel Díaz-llopisJosé L. MenezoJ. A. Avino MartinezC. Peris MartinezE. España Gregorisubject
Malemedicine.medical_specialtyEye diseaseVisual AcuityBlindnessOphthalmoscopy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOphthalmologyRetinal Vein OcclusionCoagulopathyMedicineHumansPoint MutationFluorescein AngiographyClotting factormedicine.diagnostic_testbusiness.industryGenetic VariationRetinalGeneral MedicineMiddle Agedmedicine.diseaseFluorescein angiographyThrombosisSurgeryOphthalmologychemistry030221 ophthalmology & optometryBranch retinal vein occlusionProthrombinbusiness030217 neurology & neurosurgerydescription
Purpose To describe a case of branch retinal vein occlusion (BRVO) in a patient who tested positive for the 20210 A allele of the prothrombin (PT) gene. Methods A 48-year-old man had visual loss in the right eye secondary to BRVO confirmed by ophthalmoscopy and fluorescein angiography. His medical history was not remarkable for common risk factors for retinal occlusive diseases. Results Laboratory tests for hypercoagulability were positive for PT 20210 A variant. The patient's family tested negative for the PT variant. Conclusions Laboratory tests for coagulopathy, including the PT 20210 A variant, should be added to the examination of patients with central or BRVO, especially if most common risk factors for thrombosis have been excluded.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2000-04-01 | European journal of ophthalmology |